Harmony Biosciences Competitors

Harmony Biosciences (NASDAQ:HRMY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Harmony Biosciences and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Harmony Biosciences presently has a consensus price target of $51.6667, suggesting a potential upside of 81.92%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 41.14%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Ionis Pharmaceuticals.

Earnings and Valuation

This table compares Harmony Biosciences and Ionis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Harmony Biosciences.

Profitability

This table compares Harmony Biosciences and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Harmony Biosciences on 7 of the 9 factors compared between the two stocks.

Sarepta Therapeutics (NASDAQ:SRPT) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares Sarepta Therapeutics and Harmony Biosciences' top-line revenue, earnings per share and valuation.

Harmony Biosciences has lower revenue, but higher earnings than Sarepta Therapeutics.

Insider & Institutional Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sarepta Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Sarepta Therapeutics and Harmony Biosciences, as reported by MarketBeat.

Sarepta Therapeutics currently has a consensus target price of $150.4762, suggesting a potential upside of 110.40%. Harmony Biosciences has a consensus target price of $51.6667, suggesting a potential upside of 81.92%. Given Sarepta Therapeutics' higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Harmony Biosciences.

Summary

Sarepta Therapeutics beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.

Harmony Biosciences (NASDAQ:HRMY) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Harmony Biosciences and Allakos' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Harmony Biosciences and Allakos, as reported by MarketBeat.

Harmony Biosciences currently has a consensus target price of $51.6667, indicating a potential upside of 81.92%. Allakos has a consensus target price of $181.50, indicating a potential upside of 72.32%. Given Harmony Biosciences' higher probable upside, equities analysts plainly believe Harmony Biosciences is more favorable than Allakos.

Institutional & Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Harmony Biosciences and Allakos' net margins, return on equity and return on assets.

Blueprint Medicines (NASDAQ:BPMC) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Blueprint Medicines and Harmony Biosciences' gross revenue, earnings per share (EPS) and valuation.

Harmony Biosciences has lower revenue, but higher earnings than Blueprint Medicines.

Profitability

This table compares Blueprint Medicines and Harmony Biosciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Blueprint Medicines and Harmony Biosciences, as reported by MarketBeat.com.

Blueprint Medicines currently has a consensus target price of $112.40, indicating a potential upside of 17.14%. Harmony Biosciences has a consensus target price of $51.6667, indicating a potential upside of 81.92%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Harmony Biosciences on 7 of the 10 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Profitability

This table compares Perrigo and Harmony Biosciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Perrigo and Harmony Biosciences, as provided by MarketBeat.

Perrigo presently has a consensus target price of $52.00, indicating a potential upside of 25.36%. Harmony Biosciences has a consensus target price of $51.6667, indicating a potential upside of 81.92%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Perrigo.

Earnings & Valuation

This table compares Perrigo and Harmony Biosciences' revenue, earnings per share (EPS) and valuation.

Perrigo has higher revenue and earnings than Harmony Biosciences.

Insider & Institutional Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Perrigo beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.

Harmony Biosciences (NASDAQ:HRMY) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for Harmony Biosciences and Schrödinger, as reported by MarketBeat.com.

Harmony Biosciences currently has a consensus target price of $51.6667, suggesting a potential upside of 81.92%. Schrödinger has a consensus target price of $85.50, suggesting a potential upside of 9.36%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Harmony Biosciences is more favorable than Schrödinger.

Valuation and Earnings

This table compares Harmony Biosciences and Schrödinger's gross revenue, earnings per share (EPS) and valuation.

Harmony Biosciences has higher earnings, but lower revenue than Schrödinger.

Profitability

This table compares Harmony Biosciences and Schrödinger's net margins, return on equity and return on assets.

Institutional and Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 41.3% of Schrödinger shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Schrödinger on 6 of the 7 factors compared between the two stocks.